The preclinical findings revealed that ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, achieved up to 41.5% weight loss in mice in a dose-dependent manner. Beyond efficacy, the drug’s design focuses on longevity; its Self Assembly Lipid Depot formulation exhibited an average half-life of 17 days in non-human primate studies. This duration is roughly seven times longer than that of retatrutide, positioning the candidate for a once-monthly dosing regimen.
In section Releases
Ascletis Targets Once-Monthly Obesity Treatment with ASC37 Peptide
In a series of diet-induced obese mouse models, Ascletis Pharma’s new triple peptide agonist ASC37 outperformed tirzepatide, demonstrating an 88% greater relative reduction in body weight. The company now plans to pursue a biologics license application for the drug, aiming for a once-monthly subcutaneous administration schedule for patients.
Jinzi Jason Wu, CEO of Ascletis, noted that the company’s decision to classify ASC37 as a biologic offers specific regulatory advantages. Under the Inflation Reduction Act, biologics qualify for a 13-year exemption from government price negotiations, compared to nine years for small molecules. Furthermore, the biologic classification restricts third-party pharmacies from compounding versions of the drug, potentially securing a more stable market position. Ascletis expects to submit the Investigational New Drug application for both the subcutaneous and oral formulations in the third quarter of 2026.
Comments (0)
No comments yet. Be the first!